COMPOSITION PHARMACEUTIQUE PERMETTANT LA PRÉVENTION OU LE TRAITEMENT DU CANCER, CONTENANT COMME PRINCIPES ACTIFS DE LA STREPTONIGRINE ET DE LA RAPAMYCINE
The present invention relates to: a pharmaceutical composition for preventing or treating cancer, containing streptonigrin and an mTOR inhibitor as active ingredients； and a composition for inhibiting angiogenesis, containing streptonigrin and a vascular endothelial growth factor (VEGF) inhibitor as active ingredients. In addition, the present invention relates to: a cancer treatment method using streptonigrin and an mTOR inhibitor, a use in the preparation of anticancer drugs and a composition to be used in cancer prevention or treatment； and a method for inhibiting angiogenesis by using streptonigrin and a VEGF inhibitor, a use in the preparation of drugs for inhibiting angiogenesis and a composition to be used in angiogenesis inhibition. When a renal cancer cell line is treated with streptonigrin, which is a TGase2 inhibitor, in combination with rapamycin, which is an mTOR inhibitor, a cancer cell death effect can be exhibited to be greater than that when cancer cells are treated with each thereof, individually, and the same synergistic effect can be exhibited even in cancer cells resistant to mTOR inhibitors.
